Citigroup Upgrades Guardant Health to Buy, Announces $40 Price Target
Portfolio Pulse from richadhand@benzinga.com
Citigroup analyst Patrick Donnelly upgrades Guardant Health (NASDAQ:GH) from Neutral to Buy and announces a $40 price target.
May 26, 2023 | 12:22 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Guardant Health (NASDAQ:GH) has been upgraded from Neutral to Buy by Citigroup analyst Patrick Donnelly, with a $40 price target.
The upgrade from Neutral to Buy by Citigroup analyst Patrick Donnelly indicates a positive outlook for Guardant Health's stock. The $40 price target suggests potential upside for the stock, which may lead to short-term price appreciation.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100